Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of UBT251 injection in adults with metabolic dysfunction-associated steatohepatitis
CTR20252753Phase 2Active
- Sponsor
- The United Laboratories International Holdings
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of UBT251 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by The United Laboratories International Holdings. Started Sep 2025; status: active.
02
Drugs
UBT251
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20252753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252753.